Role of miRNAs in regulating responses to radiotherapy in human breast cancer

Chong, Zhi Xiong; Yeap, Swee Keong; Ho, Wan Yong

doi:10.1080/09553002.2021.1864048

Cited by 12 publications

(5 citation statements)

References 116 publications

(162 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the context of breast cancer, miRNAs have demonstrated their potential to modulate the cellular response to RT [ 87 ]. Certain miRNAs exert control over key proteins involved in DNA damage response and repair, thereby influencing the sensitivity of breast cancer cells to radiation [ 88 ].…”

Section: Crosstalk Between Mirnas and Cancer Progression During Rtmentioning

confidence: 99%

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

Taeb,

Rostamzadeh,

Amini

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small RNA molecules that regulate genes and are involved in various biological processes, including cancer development. Researchers have been exploring the potential of miRNAs as therapeutic agents in cancer treatment. Specifically, targeting the mammalian target of the rapamycin (mTOR) pathway with miRNAs has shown promise in improving the effectiveness of radiotherapy (RT), a common cancer treatment. This review provides an overview of the current understanding of miRNAs targeting mTOR as therapeutic agents to enhance RT outcomes in cancer patients. It emphasizes the importance of understanding the specific miRNAs that target mTOR and their impact on radiosensitivity for personalized cancer treatment approaches. The review also discusses the role of mTOR in cell homeostasis, cell proliferation, and immune response, as well as its association with oncogenesis. It highlights the different ways in which miRNAs can potentially affect the mTOR pathway and their implications in immune-related diseases. Preclinical findings suggest that combining mTOR modulators with RT can inhibit tumor growth through anti-angiogenic and anti-vascular effects, but further research and clinical trials are needed to validate the efficacy and safety of using miRNAs targeting mTOR as therapeutic agents in combination with RT. Overall, this review provides a comprehensive understanding of the potential of miRNAs targeting mTOR to enhance RT efficacy in cancer treatment and emphasizes the need for further research to translate these findings into improved clinical outcomes.

show abstract

Section: Crosstalk Between Mirnas and Cancer Progression During Rtmentioning

confidence: 99%

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

Taeb,

Rostamzadeh,

Amini

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…A recent review identified a variety of miRNAs as key players in regulating the sensitivity and resistance of breast cancer cells to radiotherapy. Notably, among 36 identified miRNAs impacting radio-responses, 22 were found to enhance radiosensitivity, 12 contributed to radioresistance, and 2 demonstrated both effects ( 24 ).…”

Section: Long Non-coding Rna and Micrornamentioning

confidence: 99%

Innovative therapeutic strategies to overcome radioresistance in breast cancer

Arnold,

Mangesius,

Portnaia

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Despite a comparatively favorable prognosis relative to other malignancies, breast cancer continues to significantly impact women’s health globally, partly due to its high incidence rate. A critical factor in treatment failure is radiation resistance – the capacity of tumor cells to withstand high doses of ionizing radiation. Advancements in understanding the cellular and molecular mechanisms underlying radioresistance, coupled with enhanced characterization of radioresistant cell clones, are paving the way for the development of novel treatment modalities that hold potential for future clinical application. In the context of combating radioresistance in breast cancer, potential targets of interest include long non-coding RNAs (lncRNAs), micro RNAs (miRNAs), and their associated signaling pathways, along with other signal transduction routes amenable to pharmacological intervention. Furthermore, technical, and methodological innovations, such as the integration of hyperthermia or nanoparticles with radiotherapy, have the potential to enhance treatment responses in patients with radioresistant breast cancer. This review endeavors to provide a comprehensive survey of the current scientific landscape, focusing on novel therapeutic advancements specifically addressing radioresistant breast cancer.

show abstract

“…In ovarian cancer (OC), miR-135a-3p, miR-200c, miR-216a and miR-340 can regulate the invasiveness of OC cells by regulating the epithelial-mesenchymal transition (EMT) program [ 82 , 83 , 84 , 85 ]. In addition, miRNAs are closely associated with the occurrence and development of many malignant tumors, such as lung cancer, pancreatic cancer and breast cancer [ 86 , 87 , 88 , 89 , 90 , 91 ].…”

Section: Epigenetics In Cancer Occurrence and Cancer Radiotherapymentioning

confidence: 99%

The Advances in Epigenetics for Cancer Radiotherapy

Wang

Han

Jin

et al. 2022

IJMS

View full text Add to dashboard Cite

Cancer is an important factor threatening human life and health; in recent years, its morbidity and mortality remain high and demosntrate an upward trend. It is of great significance to study its pathogenesis and targeted therapy. As the complex mechanisms of epigenetic modification has been increasingly discovered, they are more closely related to the occurrence and development of cancer. As a reversible response, epigenetic modification is of great significance for the improvement of classical therapeutic measures and the discovery of new therapeutic targets. It has become a research focusto explore the multi-level mechanisms of RNA, DNA31, chromatin and proteins. As an important means of cancer treatment, radiotherapy has made great progress in technology, methods, means and targeted sensitization after years of rapid development, and even research on radiotherapy based on epigenetic modification is rampant. A series of epigenetic effects of radiation on DNA methylation, histone modification, chromosome remodeling, RNA modification and non-coding RNA during radiotherapy affects therapeutic effects and prognosis. Starting from the epigenetic mechanism of tumorigenesis, this paper reviews the latest progress in the mechanism of interaction between epigenetic modification and cancer radiotherapy and briefly introduces the main types, mechanisms and applications of epigenetic modifiers used for radiotherapy sensitization in order to explore a more individual and dynamic approach of cancer treatment based on epigenetic mechanism. This study strives to make a modest contribution to the progress of human disease research.

show abstract

Role of miRNAs in regulating responses to radiotherapy in human breast cancer

Cited by 12 publications

References 116 publications

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

Innovative therapeutic strategies to overcome radioresistance in breast cancer

The Advances in Epigenetics for Cancer Radiotherapy

Contact Info

Product

Resources

About